Skip to content
Shuttingdown

Day One Biopharmaceuticals, Inc.

Pharmaceutical Preparations · BRISBANE · CA

Distress signal

Moderate confidence (50%)

Updated Oct 18, 2026, 12:03 AM

What is happening

Derived by rule set status-rules-2026.09.7

An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.

Latest material event: Day One Biopharmaceuticals, Inc. deregistered its securities (May 4, 2026)

Timeline

Every material event, newest first. History is never overwritten.

  1. Day One Biopharmaceuticals, Inc. deregistered its securities

    May 4, 2026

    Registration withdrawn

    • SEC EDGAR — “15-12G 1 d149766d1512g.htm 15-12G 15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-40431 DAY ONE BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) 1800 Sierra Point Parkway, Suite 200 Brisbane, CA 94005 Telephone: (650) 484-0899 (Address, including zip code, and telephone number, inc…”

  2. Day One Biopharmaceuticals, Inc. was delisted from its exchange

    Apr 23, 2026

    Delisting effective

    • SEC EDGAR — “X0203 0001354457 Nasdaq Stock Market LLC 0001845337 Day One Biopharmaceuticals, Inc. 001-40431 1800 Sierra Point Parkway Suite 200 Brisbane CA CALIFORNIA 94005 (650) 484-0899 Common Stock 17 CFR 240.12d2-2(a)(3) Tara Petta AVP 2026-04-23”

  3. Day One Biopharmaceuticals, Inc. received a delisting notice from its exchange

    Apr 22, 2026

    Delisting notice received

    • SEC EDGAR — “Item 3.01, Item 5.01 and Item 5.03 are incorporated herein by reference. Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. The disclosures under the Introductory Note of this Current Report on Form 8-K are incorporated herein by reference. On April 22, 2026, the Company (i) confirmed to the Nasdaq Stock Market LLC ( Nasdaq ) that the Offer was scheduled to expire at one minute past 11:59 p.m., Eastern Time, on April 22, 2026, (ii) notified Nasdaq of the anticipated consummation of the Merger prior to market open on April 23, 2026 and…”

Company information

Founded
—
Employees (estimate)
—
Industry
Pharmaceutical Preparations
Subindustry
—
SEC CIK
0001845337
Website
—
LinkedIn
—
Headquarters
BRISBANE, CA
Also known as
Day One Biopharmaceuticals Holding Co LLC
Legal entities
Day One Biopharmaceuticals, Inc.

Sources

Every material source used to build this profile.

  • SEC Company Submissions (TIER 1 · UNVERIFIED)

    Day One Biopharmaceuticals, Inc. — Pharmaceutical Preparations (SIC 2834) — BRISBANE, CA
    View source record

  • SEC EDGAR (TIER 1 · UNVERIFIED)

    15-12G 1 d149766d1512g.htm 15-12G 15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-40431 DAY ONE BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) 1800 Sierra Point Parkway, Suite 200 Brisbane, CA 94005 Telephone: (650) 484-0899 (Address, including zip code, and telephone number, inc…
    View source record

  • SEC EDGAR (TIER 1 · UNVERIFIED)

    X0203 0001354457 Nasdaq Stock Market LLC 0001845337 Day One Biopharmaceuticals, Inc. 001-40431 1800 Sierra Point Parkway Suite 200 Brisbane CA CALIFORNIA 94005 (650) 484-0899 Common Stock 17 CFR 240.12d2-2(a)(3) Tara Petta AVP 2026-04-23
    View source record

  • SEC EDGAR (TIER 1 · UNVERIFIED)

    Item 3.01, Item 5.01 and Item 5.03 are incorporated herein by reference. Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. The disclosures under the Introductory Note of this Current Report on Form 8-K are incorporated herein by reference. On April 22, 2026, the Company (i) confirmed to the Nasdaq Stock Market LLC ( Nasdaq ) that the Offer was scheduled to expire at one minute past 11:59 p.m., Eastern Time, on April 22, 2026, (ii) notified Nasdaq of the anticipated consummation of the Merger prior to market open on April 23, 2026 and…
    View source record

Status history

Every derived status, with the rule that produced it.

  • DISTRESS_SIGNAL → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 18, 2026, 01:31 AM

    An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.

  • DISTRESS_SIGNAL → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 18, 2026, 01:14 AM

    An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.

  • DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 15, 2026, 12:31 PM

    The company stopped being publicly listed. That happens to failing companies and to acquired ones alike.

  • DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 12, 2026, 12:04 AM

    The company stopped being publicly listed. That happens to failing companies and to acquired ones alike.

  • DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 11, 2026, 12:01 AM

    The company stopped being publicly listed. That happens to failing companies and to acquired ones alike.

  • DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 8, 2026, 04:34 AM

    The company stopped being publicly listed. That happens to failing companies and to acquired ones alike.

  • UNKNOWN → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 8, 2026, 04:34 AM

    An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.